Sal B Targets TAZ to Facilitate Osteogenesis and Reduce Adipogenesis Through MEK-ERK Pathway
Overview
Molecular Biology
Affiliations
Salvianolic acid B (Sal B), a major bioactive component of Chinese herb, was identified as a mediator for bone metabolism recently. The aim of this study is to investigate the underlying mechanisms by which Sal B regulates osteogenesis and adipogenesis. We used MC3T3-E1 and 3T3-L1 as the study model to explore the changes of cell differentiation induced by Sal B. The results indicated that Sal B at different concentrations had no obvious toxicity effects on cell proliferation during differentiation. Furthermore, Sal B facilitated osteogenesis but inhibited adipogenesis by increasing the expression of transcriptional co-activator with PDZ-binding motif (TAZ). Accordingly, TAZ knock-down offset the effects of Sal B on cell differentiation into osteoblasts or adipocytes. Notably, the Sal B induced up-expression of TAZ was blocked by U0126 (the MEK-ERK inhibitor), rather than LY294002 (the PI3K-Akt inhibitor). Moreover, Sal B increased the p-ERK/ERK ratio to regulate the TAZ expression as well as the cell differentiation. In summary, this study suggests for the first time that Sal B targets TAZ to facilitate osteogenesis and reduce adipogenesis by activating MEK-ERK signalling pathway, which provides evidence for Sal B to be used as a potential therapeutic agent for the management of bone diseases.
Wang L, Wang S, Dai X, Yue G, Yin J, Xu T Front Pharmacol. 2024; 15:1483431.
PMID: 39421672 PMC: 11484006. DOI: 10.3389/fphar.2024.1483431.
He G, Chen G, Liu W, Ye D, Liu X, Liang X Pharmaceutics. 2023; 15(9).
PMID: 37765204 PMC: 10538146. DOI: 10.3390/pharmaceutics15092235.
Zheng X, Chen L, Chen T, Cao M, Zhang B, Yuan C Animals (Basel). 2023; 13(6).
PMID: 36978655 PMC: 10044701. DOI: 10.3390/ani13061115.
Huang H, Lu Q, Ye C, Wei M, Yang C, Zhang L Cell Death Discov. 2022; 8(1):499.
PMID: 36575168 PMC: 9794779. DOI: 10.1038/s41420-022-01292-y.
A mechanistic review of chinese medicine polyphenols on bone formation and resorption.
Li Y, Li L, Li X, Luo B, Ye Q, Wang H Front Pharmacol. 2022; 13:1017538.
PMID: 36313339 PMC: 9597080. DOI: 10.3389/fphar.2022.1017538.